January 9, 2018

Adaptimmune Gets the Green Light for its New T-cell Cancer Therapy

Following successful pilot studies, Adaptimmune will increase the dose of its T-cell therapy 10-fold to see if it remains safe, while also assessing its cancer-fighting capacity.

Adaptimmune is a leader in the development of T-cell therapies for the treatment of cancer. It has been testing another one of its SPEAR T-cells in two pilot studies to determine the safety of its candidate in non-small cell lung cancer (NSCLC), as well as bladder, melanoma, and head and neck cancers. The company will continue to provide safety and efficacy throughout 2018 as it accumulates.

T-cells can have trouble detecting cancer cells, but Adaptimmune engineers them to increase their affinity by producing new sequences in the complementarity determining regions (CDRs). These share similarities with CAR-T cells, which are genetically modified to express a Chimeric Antigen Receptor (CAR), enhancing their ability to recognise cancer cells. The company’s latest SPEAR T-cells target MAGE-A10, a highly immunogenic member of the MAGE-A family of cancer-testis antigens. It is expressed by a number of solid tumors and is often associated with later stage cancer.

Read More

Back to News